Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357469 · ClinicalTrials.gov registry record · NA
Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study
A NA study of Peripheral Neuropathy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT05357469: Recruiting NA study of Peripheral Neuropathy, sponsored by M.D. Anderson Cancer Center.
NCT05357469 is a NA study of Peripheral Neuropathy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 38 participants, below the 79-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357469, a NA study of Peripheral Neuropathy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the efficacy and safety of Scrambler therapy (ST) for chemotherapy-induced painful peripheral neuropathy (CIPN), and the impact of ST on physical functioning and quality of life (QoL) in adolescents and young adults (AYA) cancer patients. In this proposed study, we will conduct a two-arm prospective, randomized wait-list controlled clinical trial to investigate the effectiveness of ST on pain and CIPN in AYAs with cancer.
Primary Outcome
Five functional scales (physical, role, cognitive, emotional, and social); nine symptom scales (fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties); and a global health status/QoL. Based on 30 questions in total, the scores range from 0 to 100.
Conditions Studied
Interventions
- DEVICE Immediate St (Scrambler Therapy)
- DEVICE Waitlist ST (Scrambler Therapy)
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What NCT05357469 shows while recruiting
NCT05357469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 79-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Immediate St (Scrambler Therapy) is the first listed.
NCT05357469 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05357469 about?
NCT05357469 is a clinical study titled "Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study". To evaluate the efficacy and safety of Scrambler therapy (ST) for chemotherapy-induced painful peripheral neuropathy (CIPN), and the impact of ST on physical functioning and quality of life (QoL) in adolescents and young adults (AYA) cancer patients. In this proposed study, we will conduct a two-ar...
What is the current status of trial NCT05357469?
This trial is currently recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2022-07-14. Estimated completion is 2026-07-31.
What conditions does trial NCT05357469 study?
This clinical trial studies the following conditions: Peripheral Neuropathy.
What interventions are being tested in trial NCT05357469?
The interventions under investigation include: Immediate St (Scrambler Therapy) (DEVICE), Waitlist ST (Scrambler Therapy) (DEVICE).
Who is sponsoring clinical trial NCT05357469?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357469 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05357469's enrollment target sits among peer trials
38 20th of 27 higher than 8 of 27 other Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
DoD AtMS for Posttraumatic Peripheral Neuropathic Pain
RECRUITING · NA
-
Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy
RECRUITING · NA
-
Reliability of Force Measurement Within the Carbon Fiber Orthosis Proximal Cuff
RECRUITING · NA
-
Massage Therapy in Reducing Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastrointestinal or Breast Malignancies
ACTIVE NOT RECRUITING · NA
-
Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI